Human Melanoma Cells under Endoplasmic Reticulum Stress Are More Susceptible to Apoptosis Induced by the BH3 Mimetic Obatoclax  by Jiang, Chen Chen et al.
Human Melanoma Cells
under Endoplasmic Reticulum
Stress Are More Susceptible
to Apoptosis Induced by the
BH3 Mimetic Obatoclax1
Chen Chen Jiang2, David Wroblewski2,
Fan Yang, Peter Hersey and Xu Dong Zhang
Immunology and Oncology Unit, Room 443,
Calvary Mater Newcastle Hospital, NSW, Australia
Abstract
Past studies have shown that melanoma cells have largely adapted to endoplasmic reticulum (ER) stress, and this
is associated with up-regulation of the antiapoptotic proteins Bcl-2 and Mcl-1. In this report, we show that the BH3
mimetic obatoclax potently overcomes resistance of melanoma cells to apoptosis induced by ER stress. Obatoclax,
as a single agent at nanomolar concentrations, was relatively ineffective in the induction of apoptosis in melanoma
cells, but treatment with obatoclax at these concentrations in combination with the ER stress inducer tunicamycin
(TM) or thapsigargin markedly enhanced apoptotic cell death. This was primarily because of the inhibition of Mcl-1 by
obatoclax, in that cotreatment with TM and another BH3 mimetic ABT737, which does not antagonize Mcl-1, caused
only minimal increases in apoptosis. Moreover, overexpression of Mcl-1 inhibited apoptosis to greater degrees than
overexpression of Bcl-2. In addition to direct inhibition of Mcl-1 by obatoclax, the combination of obatoclax and TM
caused strong up-regulation of the BH3-only protein Noxa. Small RNA interference knockdown of Noxa partially in-
hibited apoptosis induced by cotreatment with obatoclax and TM. Similarly, knockdown of Bak also blocked induc-
tion of apoptosis by the compounds. TheMcl-1/Bak interaction seemed to be disrupted more efficiently in melanoma
cells cotreated with obatoclax and TM. Taken together, these results identify obatoclax as a potent agent that over-
comes resistance of melanoma cells to ER stress–induced apoptosis and seem to have important implications in the
use of BH3 mimetics in the treatment of melanoma.
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Introduction
Melanoma continues to increase in incidence in many parts of the
world, but there is currently no curative treatment once the disease
has spread beyond the primary site because of the absence of effective
systemic therapies. This is believed to be largely due to the resistance of
melanoma cells to induction of apoptosis by available chemothera-
peutic drugs and biologic reagents [1,2]. Deregulated expression of
Bcl-2 family proteins, either as consequences of genetic alterations or
resulting from environmental stimulations, is known to play a central
role in the resistance of melanoma to apoptosis [1,2].
A number of cellular stress conditions, such as nutrient deprivation,
hypoxia, alterations in glycosylation status, and disturbances of calcium
flux, lead to accumulation and aggregation of unfolded and/ormisfolded
proteins in the endoplasmic reticulum (ER) lumen and cause so-called
ER stress [3–5]. The ER responds to stress conditions by activating a
range of stress-response signaling pathways, which is referred to as the
unfolded protein response (UPR) [3–5]. The UPR is fundamentally a
cytoprotective response, but excessive or prolonged activation of the
UPR can result in apoptosis. This involves many of the same molecules
that have important roles in other apoptotic cascades [6–9]. Among
Abbreviations: ER, endoplasmic reticulum; UPR, unfolded protein response; MAb,
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them, Bcl-2 family proteins seem to be critical because ER stress–
induced apoptosis can be inhibited by the overexpression of Bcl-2 or
its antiapoptotic homologs, suggesting that activation of proapoptotic
proteins of this family is important in initiating ER stress–mediated
apoptotic signaling [7,8]. In support of this, Bax- and Bak-deficient cells
are resistant to ER stress–induced apoptosis [7]. A number of BH3-only
proteins, including PUMA, Noxa, Bim, and BIK, have been shown to
be upregulated/activated [10–15], whereas Bcl-2 and Mcl-1 have been
reported to be downregulated [16,17], thus contributing to the induc-
tion of apoptosis by ER stress in various types of cells.
Past studies have shown that melanoma cells have largely adapted to
ER stress and are relatively resistant to ER stress–induced apoptosis
[18–20]. In contrast to down-regulation of Bcl-2 and Mcl-1 by ER
stress in many other cell types [7,15], these antiapoptotic proteins are
upregulated by the UPR in melanoma cells on ER stress [19]. Up-
regulation of Mcl-1 is of particular importance, in that it plays an im-
portant role in antagonizing PUMA and Noxa, which are also increased
in melanoma cell cells submitted to ER stress [19]. Conversely, Bcl-2
does not seem to be essential in protection of melanoma cells against
ER stress–induced apoptosis because it cannot rescue melanoma cells
deficient in Mcl-1 from apoptosis induced by ER stress [19]. Up-
regulation ofMcl-1 therefore seems to be an important adaptive mecha-
nism for melanoma cells to survive ER stress conditions.
Small-molecule mimics of BH3-only proteins are emerging as prom-
ising anticancer agents by inhibiting antiapoptotic Bcl-2 family proteins
[21–25]. Obatoclax, also known as GX015-070 (Gemin X Biotechnol-
ogies, Inc, Montreal, Quebec, Canada), was identified by chemical li-
brary screening to bind the hydrophobic groove of antiapoptotic Bcl-2
family proteins and antagonize their function [23,25]. In contrast to
another BH3 mimetic, ABT737 (Abbott Laboratories, Abbott Park, IL),
which disables Bcl-2 and Bcl-XL but does not inhibit Mcl-1 [21,22],
obatoclax can efficiently neutralize Mcl-1 [23,25]. It has been reported
that obatoclax can potently kill some types of cancer cells, such as mye-
loma cells, as a single agent [26], and enhance apoptosis induced by
various apoptotic stimuli such as tumor necrosis factor–related apoptosis–
inducing ligand and the proteasome inhibitor bortezomib [23,24].
We have examined the apoptosis-inducing potential of obatoclax
in melanoma cells submitted to acute ER stress. In this report, we
show that although obatoclax at nanomolar concentrations is relatively
ineffective in induction of apoptosis in melanoma cells, it potently
overcomes resistance of melanoma cells to apoptosis induced by ER
stress, and this is primarily due to the inhibition of Mcl-1. We dem-
onstrate that obatoclax triggers further increases in the levels of Noxa
in melanoma cells undergoing acute ER stress, which in turn cooper-
ates with obatoclax to release Bak from Mcl-1, thus activating the
mitochondrial apoptotic pathway. These results identify obatoclax as a
potent agent that targets a major adaptive mechanism to ER stress in
melanoma and suggest that combinations of obatoclax and agents that
induce ER stress may be a useful strategy in the treatment of melanoma.
Materials and Methods
Cell Lines
Human melanoma cell lines Mel-RM, MM200, IgR3, Mel-CV,
Sk-Mel-28, and ME4405 have been described previously [19,27].
They were cultured in Dulbecco’s modified Eagle medium containing
5% fetal calf serum (Commonwealth Serum Laboratories, Melbourne,
Australia).Melanocytes were kindly provided byDr. P. Parsons (Queens-
land Institute of Medical Research, Brisbane, Australia) and cultured
in medium supplied by Clonetics (Edward Kellar, Victoria, Australia).
Fresh Melanoma Isolates
Isolation of melanoma cells from fresh surgical specimens was carried
out as described previously [28,29].
Antibodies, Recombinant Proteins, and Other Reagents
Tunicamycin (TM) and thapsigargin (TG) were purchased from
Sigma Chemical, Co (Castle Hill, Australia). They were dissolved in di-
methyl sulfoxide and made up in stock solutions of 1 mM. Obatoclax
(GX15-070) was kindly supplied by Gemin X Biotechnologies, Inc.
ABT737 was kindly provided by Abbott Laboratories. Obatoclax and
ABT737 were dissolved in dimethyl sulfoxide and made up in stock
solutions of 5 mM. The mouse monoclonal antibodies (MAbs) against
Bcl-2, Bcl-XL, and Mcl-1 and the rabbit polyclonal antibodies (Abs)
against Bak and Bax were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). TheMAb against Noxa and the polyclonal Ab against
Bim were purchased from Imgenex (San Diego, CA). The rabbit poly-
clonal Ab against PUMA and the mouse MAb against cleaved form
of poly(ADP-ribose) polymerase (PARP) were from Cell Signaling
Technology (Beverly, MA). The mouse MAb against cytochrome c was
from Pharmingen (Bioclone, Marrickville, Australia). The rabbit poly-
clonal Ab against caspase-3 was from Stressgen (Victoria, BC, Canada).
Isotype control Abs used were the ID4.5 (mouse immunoglobulin G
[IgG] 2a) MAb against Salmonella typhi supplied by Dr. L. Ashman
(Institute for Medical and Veterinary Science, Adelaide, Australia), the
107.3 mouse IgG1 MAb purchased from Pharmingen (Bioclone), and
rabbit IgG from Sigma Chemical, Co.
Apoptosis
Quantitation of apoptotic cells by measurement of sub-G1 DNA
content using the propidium iodide method was carried out as de-
scribed elsewhere [19,28].
Mitochondrial Membrane Potential
Melanoma cells were seeded at 1 × 105 cells/well in 24-well plates and
allowed to reach exponential growth for 24 hours before treatment.
Changes in themitochondrial membrane potential (ΔΨm) were studied
by staining the cells with the cationic dye, JC-1, according to the manu-
facturer’s instructions (Molecular Probes, Eugene, OR) as described
previously [30].
Western Blot Analysis
Western blot analysis was carried out as described previously [19,27].
Labeled bands were detected by Immun-Star HRP Chemiluminescent
Kit, and images were captured and the intensity of the bands was quan-
titated with the Bio-Rad VersaDoc image system (Bio-Rad, Regents
Park, NSW, Australia).
Immunoprecipitation
Methods used were as described previously with minor modification
[31]. Briefly, 100 μl of lysates were precleared by incubation with 20 μl
of a mixture of protein A and protein G sepharose packed beads (Santa
Cruz Biotechnology) in a rotator at 4°C for 2 hours and then with 20 μl
of fresh packed beads overnight. Twenty micrograms of anti–Mcl-1 Ab
or control immunoglobulin was then added to the lysates and rotated at
4°C for 2 hours. The beads were then pelleted by centrifugation. The re-
sulting supernatants (nonprecipitated fractions) were collected. The beads
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Figure 1. Induction of ER stress renders melanoma cells more sensitive to obatoclax-induced apoptosis. (A and B) Obatoclax at nanomolar
concentrations is relatively ineffective in induction of apoptosis inmelanoma cells. (A) Mel-RM andMM200 cells were treatedwith obatoclax
at indicated concentrations for 24 or 48 hours. (B) Melanoma cells and melanocytes were treated with obatoclax at 1 μM for 48 hours.
Apoptosis was measured by the propidium iodide method using flow cytometry. Data shown are the mean ± SE of three individual experi-
ments. (C) Mel-RM and MM200 cells were treated with obatoclax at 1 μM (upper panel) or 100 nM (low panel), TM (3 μM), or the combi-
nation TM and obatoclax at 1 μM (upper panel) or 100 nM (low panel) for 24 or 48 hours. Apoptosis was measured by the propidium iodide
method using flow cytometry. Data shown are the mean ± SE of three individual experiments. (D) Mel-RM and MM200 cells were treated
with obatoclax (1 μM), TM (3 μM), or the combination of both for 24 hours. Whole cell lysates were subjected to Western blot analysis. The
cleaved form of PARP was detected by an Ab that specifically recognized the cleaved PARP. Data shown are representative of three indi-
vidual experiments. (E) Melanoma cells and melanocytes were treated with obatoclax (1 μM), TM (3 μM), or the combination of both for
48 hours. Apoptosis was measured by the propidium iodide method using flow cytometry. Data shown are the mean ± SE of three indi-
vidual experiments. (F) Melanoma cells were treated with obatoclax (1 μM), TG (1 μM), or the combination of both for 48 hours. Apoptosis
was measured by the propidium iodide method using flow cytometry. Data shown are the mean ± SE of three individual experiments.
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were washed five times with ice-cold lysate buffer before elution of the
proteins from the beads in lysate buffer at room temperature for 1 hour.
The resulting immunoprecipitates were then subjected to sodiumdodecyl
sulfate–polyacrylamide gel electrophoresis and Western blot analysis.
Plasmid Vector and Transfection
Stable Mel-RM and MM200 transfectants of Bcl-2 and Mcl-1
were established using the pEF-Puro vector carrying human Bcl-2
kindly provided by Dr. David Vaux (Walter and Eliza Hall Institute,
Melbourne, Victoria, Australia) and p3XFLAG-CMV-10 carrying
human Mcl-1 kindly provided by Dr. Xiaodong Wang (Howard
Hughes Medical Institute, Dallas, TX), respectively, as reported before
[19]. Briefly, Melanoma cells were seeded at 1 × 105 cells per well
in 24-well plate 24 hours before transfection. Cells were transfected
with 0.8 μg of plasmid as well as the empty vector (Sigma-Aldrich)
in Opti-MEMmedium (Invitrogen, Carlsbad, CA) with Lipofectamine
2000 reagent (Invitrogen) according to the manufacturer’s protocol.
Six hours after transfection, the cells were switched into antibiotic-free
medium containing 5% fetal calf serum for a further 24 hours. Cells
were then passaged at 1:10 into fresh medium for a further 24 hours
followed by G418 (Sigma-Aldrich) selection.
Small RNA Interference
The small RNA interference (siRNA) constructs used were obtained
as the siGENOME SMARTpool reagents (Dharmacon, Lafayette,
CO), the siGENOME SMARTpool Bak (M-003305-02-0010), the
siGENOMESMARTpool Bax (M-003308-03-0010), the siGENOME
SMARTpool Mcl-1 (M-004501-04-0010), the siGENOME SMART-
pool PUMA (M-004380-01-0010), the siGENOME SMARTpool
Noxa (M-026087-00-0010), and the siGENOME SMARTpool Bim
(M-004383-01-0010). The nontargeting siRNA control, SiConTRol-
Non-targeting SiRNA pool (D-001206-13-20), was also obtained from
Dharmacon. Transfection of siRNA pools was carried out as described
previously [19,27].
Results
Obatoclax at Nanomolar Concentrations Is Relatively
Ineffective in Induction of Apoptosis of Melanoma Cells
Obatoclax as a single agent has been shown to be a potent apoptosis
inducer in some types of cancer cells, such as myeloma cells, with a
mean half-maximal inhibitory concentration value of 246 nM [26].
To study the apoptosis-inducing potential of obatoclax in melanoma
Figure 1. (continued).
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cells, we treated Mel-RM and MM200 cells with the compound at
varying concentrations up to 1 μM for 24 and 48 hours. As shown
in Figure 1A, obatoclax did not induce apoptosis of the cells at 24 hours
after treatment. By 48 hours, it caused apoptosis in approximately 32%
and 26% of Mel-RM and MM200 cells, respectively, when used at
500 to 1000 nM. A summary of studies in a panel of melanoma cell
lines and fresh melanoma isolates and a melanocyte line treated with
obatoclax at 1 μM for 48 hours are shown in Figure 1B. Although
obatoclax induced varying degrees of apoptosis, none of the melanoma
cell lines or fresh isolates displayed a half-maximal inhibitory concen-
tration value lower than 1 μM. These results suggest that obatoclax at
nanomolar concentrations is relatively ineffective in the induction of
apoptosis of melanoma cells. Of note, obatoclax did not induce signif-
icant apoptotic cell death in melanocytes (<10% apoptotic cells).
Induction of ER Stress Renders Melanoma Cells More
Sensitive to Obatoclax-Induced Apoptosis
Previous studies have shown that most melanoma cell lines are not
sensitive to ER stress–induced apoptosis, and this is associated with
the up-regulation of the antiapoptotic Bcl-2 family proteins Mcl-1
and Bcl-2 [18–20]. To test whether obatoclax can reverse the resis-
tance of melanoma cells to apoptosis under ER stress [23,25], we
Figure 2. Increased induction of apoptosis by cotreatment with obatoclax and TM is primarily due to inhibition of Mcl-1. (A) Mel-RM and
MM200 cells were treated with ABT737 (2 μM), TM (3 μM), or the combination of both for 24 or 48 hours. Apoptosis was measured by
the propidium iodide method using flow cytometry. Data shown are the mean ± SE of three individual experiments. (B) Mel-RM and
MM200 cells were treated with TM (3 μM), ABT737 (2 μM), obatoclax (1 μM), the combination of TM and ABT737, or the combination of TM
and obatoclax for 24 hours before measurement of ΔΨm by JC-1 staining in flow cytometry. The number in each left bottom quadrant
represents the percentage of cells with reduction in ΔΨm. Data shown are representative of three individual experiments. (C) Mel-RM
and MM200 cells were treated with TM (3 μM), ABT737 (2 μM), obatoclax (1 μM), the combination of TM and ABT737, or the combination
of TM and obatoclax for 24 hours. Isolated cytosolic fractions were subjected to Western blot analysis. Data shown are representative of
three individual experiments. (D) Mel-RM cells overexpressing Bcl-2 (left panel) were treated with obatoclax (1 μM), TM (3 μM), or the com-
bination of both for 48 hours (right panel). Apoptosis was measured by the propidium iodide method using flow cytometry. Data shown are
the mean ± SE of three individual experiments. (E) Mel-RM cells overexpressing Mcl-1 (left panel) were treated with obatoclax (1 μM), TM
(3 μM), or the combination of both for 48 hours (right panel). Apoptosis was measured by the propidium iodide method using flow cyto-
metry. Data shown are the mean ± SE of three individual experiments.
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treated Mel-RM and MM200 cells with obatoclax at 1 μM or 100
nM in the presence of the classic ER stress inducer TM. As reported
elsewhere, TM alone induced only moderate levels of apoptosis
(<10% apoptotic cells) even at 48 hours after treatment [19,27]. Co-
treatment with TM and obatoclax at 1 μM or 100 nM resulted in
marked increases in apoptotic cell death in both cell lines at 24 and
48 hours in comparison with treatment with obatoclax alone (Fig-
ure 1C ). The percentage of apoptotic cells at 48 hours after co-
treatment reached 95% and 80%, respectively, in Mel-RM and
MM200 when obatoclax was used at 1 μM. Enhancement of apop-
tosis by cotreatment with TM and obatoclax in melanoma cells was
also evidenced by increased activation of caspase-3 and cleavage of its
substrate PARP (Figure 1D). Figure 1E shows that cotreatment with
TM and obatoclax for 48 hours resulted in enhanced apoptosis in a
panel of melanoma cell lines and fresh melanoma isolates. Although
TM alone induced apoptosis in approximately 28% of melanocytes
[27], there was no further increase in the levels of apoptosis after
cotreatment with obatoclax and TM (Figure 1E ). Similar to TM, co-
administration of another classic ER stress inducer TG and obatoclax
also enhanced the induction of apoptosis in melanoma cells
(Figure 1F ). Together, these results indicate that obatoclax is more
effective in the induction of apoptosis in melanoma cells undergoing
acute ER stress.
Increased Induction of Apoptosis by Obatoclax in Melanoma
Cells Undergoing ER Stress Is Primarily Due to the
Inhibition of Mcl-1
To differentiate the roles of inhibition of Mcl-1 and inhibition of
Bcl-2 in the enhancement of obatoclax-induced apoptosis in melanoma
cells cotreated with TM, we exposedMel-RM andMM200 cells to TM
in combination with another BH3mimetic ABT737 that inhibits Bcl-2
but not Mcl-1 [22,23]. Figure 2A shows that even when used at 2 μM,
ABT737 alone induced only moderate levels of apoptosis (<10%)
in both cell lines at 48 hours after treatment. The combination of
ABT737 and TM resulted in increased apoptotic cell death at 24 and
48 hours. However, the overall levels of apoptosis were markedly lower
than those induced by cotreatment with obatoclax and TM (P < .01,
2-tailed Student’s t test; Figures 1C and 2A).
We compared mitochondrial apoptotic events induced by the com-
bination of obatoclax and TMwith those by cotreatment with ABT737
and TM. As shown in Figure 2 (B and C), relative to treatment with
obatoclax alone, the combination of obatoclax and TM induced
marked increases in the reduction in ΔΨm and in the mitochondrial
release of cytochrome c as shown by elevated cytosolic levels of cyto-
chrome c inMel-RM andMM200 cells. ABT737 alone induced amini-
mal reduction in ΔΨm and mitochondrial release of cytochrome c, but
the combination of ABT737 and TM resulted in enhanced induction
of these mitochondrial apoptotic events. However, the overall levels of
reduction in ΔΨm and cytosolic expression of cytochrome c induced by
cotreatment with ABT737 and TM were noticeably lower than those
induced by the combination of obatoclax and TM.
To further confirm the roles of inhibition of Mcl-1 and inhibition of
Bcl-2 in obatoclax-induced apoptosis in melanoma cells submitted to
ER stress, we cotreated Mel-RM cells that had been stably transfected
with complementary DNA encoding Bcl-2 or Mcl-1 with obatoclax
and TM (Figure 2, D and E ) [19]. Overexpression of either Mcl-1
or Bcl-2 inhibited apoptosis induced by the combination of the com-
pounds, but the degrees of inhibition by the overexpression of Mcl-1
Figure 2. (continued).
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were significantly greater than those by the overexpression of Bcl-2
(P < .01, 2-tailed Student’s t test; Figure 2, D and E).
Induction of ER Stress Alters the Expression Profile of Bcl-2
Family Proteins in Response to Obatoclax
Induction of ER stress is known to result in increased expression of
the BH3-only proteins PUMA andNoxa and the antiapoptotic proteins
Bcl-2 andMcl-1 [19]. As shown in Figure 3, exposure ofmelanoma cells
to obatoclax caused even greater degrees of up-regulation of PUMA,
Noxa, Bcl-2, and Mcl-1. In addition, the BH3-only protein Bim was
also increased in melanoma cells treated with obatoclax. Notably, co-
treatment with both agents did not cause any further changes in the
levels of PUMA, Bcl-2, and Bim. However, the levels of expression of
Noxa were markedly higher in cells cotreated with obatoclax and TM
than those in cells treated with either compound alone (Figure 3).
In contrast, the levels of Mcl-1 were even lower than those induced
by obatoclax alone (Figure 3).
Inhibition of Noxa or Bak Partially Blocks Obatoclax-Induced
Apoptosis in Melanoma Cells under ER Stress
To study the roles of BH3-only proteins in enhancement of induc-
tion of apoptosis by cotreatment with obatoclax and TM, we trans-
fected siRNA pools for Noxa, PUMA, and Bim into Mel-RM and
MM200 cells, respectively. Figure 4 (A–C) shows that siRNA reduced
their expression by at least 70% but had no effect on the expression of
their relative Bcl-2 or Mcl-1. Knockdown of Noxa by siRNA partially
blocked apoptosis induced by obatoclax alone (Figure 4D). Similarly,
inhibition of Noxa partially blocked apoptosis induced by cotreatment
with obatoclax and TM (P < .01, 2-tailed Student’s t test; Figure 4D).
In contrast, knockdown of PUMA or Bim by siRNA had only minimal
effects on apoptosis induced by obatoclax or obatoclax in combination
with TM (Figure 4D).
We examined the role of the multidomain Bcl-2 family protein,
Bak, in apoptosis induced by cotreatment with obatoclax and TM
in Mel-RM and MM200 cells in which Bak was knocked down by
siRNA (Figure 5A). Inhibition of Bak significantly inhibited apoptosis
induced by either obatoclax alone or by cotreatment with obatoclax and
TM (P < .01, 2-tailed Student’s t test; Figure 5B). As shown in Figure 5
(C and D), inhibition of the other multidomain Bcl-2 family protein
Bax by transfecting a siRNA pool into Mel-RM and MM200 cells also
blocked the induction of apoptosis by obatoclax or obatoclax in com-
bination with TM, but the degrees of inhibition were less pronounced
than those resulting from the inhibition of Bak.
Mcl-1/Bak Interaction Is Disrupted by Obatoclax More
Efficiently in Melanoma Cells Undergoing ER Stress
In the absence of apoptotic stimulation, Bak is known to be seques-
tered byMcl-1 and Bcl-XL on the outer mitochondrial membrane [32].
Release of Bak from these antiapoptotic proteins by replacement
with BH3-only proteins plays a key role in permeabilizing the outer
mitochondrial membrane [32]. We studied the interactions between
Mcl-1 and Bak andNoxa inMel-RM andMM200 cells before and after
treatment with obatoclax in the absence or presence of TM. As shown in
Figure 6, Western blot analysis of precipitates resulting from immu-
noprecipitation with an Ab against Mcl-1 revealed that treatment with
obatoclax led to reduced association between Bak and Mcl-1 and, in-
triguingly, increased interactions between Noxa and Mcl-1. Notably,
there was little Bak coprecipitated with Mcl-1 in cells cotreated with
obatoclax and TM (Figure 6). In contrast, the levels of Noxa in Mcl-1
precipitates from cells cotreated with obatoclax and TM seemed even
higher than those from cells treated with obatoclax alone (Figure 6).
Discussion
Previous studies have shown that melanoma cells have largely adapted
to ER stress and are largely resistant to ER stress–induced apoptosis
[18–20]. One of the major adaptive mechanisms seems to be up-
regulation of the antiapoptotic Bcl-2 family protein Mcl-1, which plays
a critical role in preserving outer mitochondrial membrane integrity in
melanoma cells submitted to ER stress [19]. In the present study, we
show that the novel BH3 mimetic, obatoclax, potently disrupts the
adaptive mechanism and overcomes resistance of melanoma cells to
ER stress–induced apoptosis. Moreover, we demonstrate that the
BH3-only protein Noxa is preferentially increased by obatoclax, which
in turn, along with Bak, plays a dominant role in induction of apoptosis
by obatoclax in melanoma cells undergoing ER stress.
Both Bcl-2 and Mcl-1 can be upregulated by the ER stress response
in melanoma cells [19], but enhancement of apoptosis induced by
obatoclax in melanoma cells undergoing acute ER stress induced by
cotreatment with TM is primarily due to the inhibition of Mcl-1. This
was shown by the limited ability of another BH3 mimetic ABT737,
which is known to inhibit Bcl-2 but not Mcl-1 [22,23], to enhance mi-
tochondrial apoptotic events and induction of apoptosis in melanoma
cells under ER stress. In addition, overexpression of Mcl-1 almost com-
pletely blocked apoptosis, whereas overexpression of Bcl-2 hadmarkedly
fewer effects on apoptosis induced by the combination of obatoclax
and TM.We have previously shown that overexpression of Bcl-2 could
not rescue melanoma cells with deficient Mcl-1 expression from ER
stress–induced apoptosis [19]. Together, these findings are supported
Figure 3. Obatoclax alters the expression profile of Bcl-2 family
proteins in melanoma cells under ER stress. Mel-RM and MM200
cells were treated with obatoclax (1 μM), TM (3 μM), or the combi-
nation of both for 36 hours. Whole cell lysates were subjected to
Western blot analysis. Data shown are representative of three indi-
vidual experiments.
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by reports showing that obatoclax can overcome Mcl-1–mediated
resistance to apoptosis [21,23–25], whereas ABT737 is relatively in-
effective in increasing sensitivity to apoptosis when Mcl-1 is involved
in the resistance [22,23].
Intriguingly, obatoclax alone induced marked up-regulation of Bcl-2
and Mcl-1 in melanoma cells. This seemed to be melanoma cell–
specific, in that the compound did not cause any increase in Bcl-2
and Mcl-1 in other types of cancer cells [21,23,25]. It is conceivable
that up-regulation of Bcl-2 and Mcl-1 may increase the amount of
obatoclax needed to neutralize these proteins, thus rendering mela-
noma cells relatively resistant to obatoclax-induced apoptosis. Notably,
obatoclax also upregulated the BH3-only proteins Noxa, PUMA, and
Bim in melanoma cells. Although Bim has been reported to be in-
creased by obatoclax [23], the present study seemed to be the first to
show that Noxa and PUMA can be similarly upregulated by the com-
pound in melanoma cells. The unexpected effect of obatoclax on the
expression of multiple Bcl-2 family proteins including Bcl-2 and Mcl-1
indicates that this compound possesses more complex biologic effects
on melanoma cells than just binding to and inhibiting antiapoptotic
Bcl-2 family proteins [23,24].
Of note, the levels ofMcl-1 inmelanoma cells cotreated withTMand
obatoclax were lower than those induced by obatoclax alone, but the
BH3-only protein Noxa, which was upregulated by TM or obatoclax
alone, was further increased by cotreatment with the agents. Binding
of Noxa to Mcl-1 has been shown to target the latter for proteasome-
mediated degradation [32,33], so the reduced Mcl-1 expression may
be due to increased Noxa that precipitated Mcl-1 degradation. Another
possibility is that Mcl-1 was degraded by caspase-3 activity that was
enhanced in melanoma cells cotreated with obatoclax and TM [34,35].
Noxa seemed to be themain BH3-only protein involved in induction
of apoptosis by obatoclax in melanoma cells undergoing ER stress, as
shown by its strong up-regulation in response to cotreatment with
obatoclax andTMandby inhibition of apoptosis whenNoxawas knocked
down by siRNA. This is consistent with the finding that inhibition of
Figure 4. Inhibition of Noxa partially inhibited enhancement of induction of apoptosis by cotreatment with obatoclax and TM. (A–C) Mel-RM
and MM200 cells were transfected with the control, Noxa (A), PUMA (B), or Bim (C) siRNA. Twenty-four hours later, whole cell lysates were
subjected toWestern blot analysis of Noxa, PUMA, or Bim expression. Western blot analysis ofMcl-1 or Bcl-2 was included as controls. The
relative expression levels of Noxa, PUMA, and Bim were inhibited by 86%, 90%, and 82%, respectively, in Mel-RM cells, and by 82%, 87%
and 80%, respectively, in MM200 cells. Data shown are representative of three individual experiments. (D) Mel-RM and MM200 cells
were transfected with the control, Noxa (A), PUMA (B), or Bim (C) siRNA. Twenty-four hours later, cells were treated with obatoclax
(1 μM), TM (3 μM), or the combination of both for 48 hours. Apoptosis wasmeasured by the propidium iodidemethod using flow cytometry.
Data shown are the mean ± SE of three individual experiments.
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Figure 5. Inhibition of Bak partially blocks enhancement in induction of apoptosis by obatoclax and TM. (A) Mel-RM and MM200 cells
were transfected with the control or Bak siRNA. Whole cell lysates were subjected to Western blot analysis. The relative expression
levels of Bak were inhibited by 84% and 86% in Mel-RM and MM200 cells, respectively. Data shown are representative of three individual
experiments. (B) Mel-RM and MM200 cells with Bak knocked down by siRNA were treated with obatoclax (1 μM), TM (3 μM), or the com-
bination of both for 48 hours. Apoptosis was measured by the propidium iodide method using flow cytometry. Data shown are the mean ±
SE of three individual experiments. (C) Mel-RM and MM200 cells were transfected with the control or Bax siRNA. Twenty-four hours later,
whole cell lysates were subjected toWestern blot analysis. The relative expression levels of Bak were inhibited by 84% and 78% in Mel-RM
and MM200 cells, respectively. Data shown are representative of three individual experiments. (D) Mel-RM and MM200 cells were trans-
fected with the control or Bax siRNA. Twenty-four hours later, cells were treated with obatoclax (1 μM), TM (3 μM), or the combination of
both for 48 hours. Apoptosis was measured by the propidium iodide method using flow cytometry. Data shown are the mean ± SE of three
individual experiments.
Figure 6. Obatoclax disrupts the Bak/Mcl-1 interaction more efficiently in melanoma cells undergoing ER stress. Mel-RM and MM200 cells
were treated with obatoclax (1 μM), TM (3 μM), or the combination of both for 24 hours. Whole cell lysates were subjected to immunopre-
cipitation with an Ab against Mcl-1. The resulting precipitates and nonprecipitated fractions were then subjected toWestern blot analysis of
Mcl-1, Noxa, and Bak. The arrowhead points to bands generated by the immunoglobulin light chain. Western blot data are representative of
three individual experiments.
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Mcl-1 played an essential role in enhanced induction of apoptosis
because Noxa can only be antagonized by Mcl-1 but not Bcl-2 [36].
Mcl-1 has been suggested to have a unique role in protection against
apoptosis, in that elimination of Mcl-1 was shown to be required for
induction of apoptosis by various stimuli [37]. It seems that the re-
duced Mcl-1 expression would facilitate obatoclax-mediated inactiva-
tion of its function as an antiapoptotic effector.
Obatoclax is known to overcomeMcl-1–mediated resistance to apop-
tosis induced by the proteasome inhibitor bortezomib in mouse mela-
noma and human lymphoma cells [23,24]. Interestingly, bortezomib
has been shown to induce ER stress in a number of types of cells includ-
ing melanoma cells [38,39]. However, as a proteasome inhibitor, borte-
zomib may elicit a variety of changes in gene expression in tumor cells
that may not be necessarily related to induction of ER stress [40,41].
In melanoma, it has been shown that bortezomib induced apoptosis
by up-regulation of Noxa through a c-Myc–mediated transcriptional
mechanism [41]. The effect of obatoclax onmelanoma cells treatedwith
bortezomibmay, therefore, not necessarily reflect its effect onmelanoma
cells undergoing ER stress, although in both cases, obatoclax as a BH3
mimetic would be expected to enhance induction of apoptosis. As far
as we are aware, the changes in the expression profile of Bcl-2 family
proteins in response to obatoclax in melanoma cells undergoing ER
stress have not been previously observed in melanoma or other cancer
cells treated with bortezomib [22,24].
siRNA knockdown of Bak showed that it was also important for the
induction of apoptosis by obatoclax in melanoma cells undergoing ER
stress. It is believed that Bak is sequestered by Mcl-1 and Bcl-XL on the
outer mitochondrial membrane in intact cells [32] and that competitive
binding of these antiapoptotic proteins by BH3-only proteins frees Bak,
allowing it to oligomerize and trigger outer mitochondrial permeability
[32]. In this study, there was much less Bak coprecipitated with Mcl-1
in melanoma cells cotreated with obatoclax and TM than those treated
with obatoclax alone, indicating that the interaction between Bak and
Mcl-1 was disrupted more efficiently by obatoclax in melanoma cells
undergoing ER stress. This, along with the reduced Mcl-1 expression,
may cooperate with obatoclax to release Bak from Mcl-1.
Because Bak-mediated apoptosis also requires neutralization of
Bcl-XL [32], it is conceivable that other BH3-only proteins such as
PUMA and Bim that can engage Bcl-XL also play roles in the induction
of apoptosis by the combination of obatoclax and TM.However, in this
study, inhibition of PUMA or Bim by siRNA seemed to have onlymini-
mal effects on apoptosis induced by cotreatment with the compounds.
The reduced levels of Mcl-1 in melanoma cells cotreated with obatoclax
and TM argue against a major role of PUMA and Bim in antagoniz-
ing Mcl-1, in that engagement of Bim or PUMA is known to stabilize
Mcl-1 against degradation [33,42]. Nevertheless, it is noteworthy that
cotreatment with ABT737 and TM also resulted in a slight increase in
apoptosis. This indicates that inhibition of antiapoptotic Bcl-2 family
proteins other thanMcl-1may be involved in enhancement of apoptosis
induced by obatoclax inmelanoma cells undergoing ER stress. Similarly,
inhibition of Bax by siRNA knockdown also reduced the levels of apop-
tosis, albeit to a lesser extent.
Adaptation to ER stress is known to contribute to resistance of mela-
noma cells to various chemotherapeutic drugs [29,43]. The present
study, along with our previous studies showing that up-regulation of
Mcl-1 is an important adaptive mechanism by which melanoma cells
survive ER stress [19], demonstrates that the BH3 mimetic obatoclax
is a potent agent that targets this adaptive mechanism and overcomes
resistance of melanoma cells to ER stress–induced apoptosis. Impor-
tantly, these findings also applied to fresh melanoma isolates that may
reflect more closely the susceptibility of melanoma cells in vivo. These
results suggest that treatment with obatoclax in combination with
agents that can induce ER stress such as cisplatin and sorafenib may
be particularly effective in the treatment of melanoma [29,44]. Co-
treatment with obatoclax and TM did not induce more killing of mela-
nocytes than TM alone, suggesting the combination of obatoclax and
ER stress inducers may have limited cytotoxicity toward normal tissues.
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